Effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism in pre-dialysis patients with hyperkalemia

Effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism in pre-dialysis patients with hyperkalemia - Effects of polystyrene sulfonate on mineral and bone metabolism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021955

Enrollment

Registered

2016-04-17

Start date

2015-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pre-dialysis CKD patients

Interventions

sodium polystyrene sulfonate (SPS) 15g 4weeks calcium polystyrene sulfonate (CPS) 15g 4weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: eGFR<30ml/min, serum potassium level>5.0mmol/l

Exclusion criteria

Exclusion criteria: We excluded patients who were already given PSs for hyperkalemia, and diagnosed with acute kidney injury, liver injury, or patients in the perioperative period.

Design outcomes

Primary

Measure	Time frame
Changes of potassium, calcium, and magnesium levels	—

Countries

Japan

Contacts

Public ContactKei Fukami

Kurume University Division of Nephrology, Department of Medicine

fukami@med.kurume-u.ac.jp0942-35-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026